Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PCI 0123

Known as: PCI-0123 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
We have investigated the pharmacokinetics (PK) of Lutetium Texaphyrin (Lu-Tex), a second-generation photosensitizer, in the… Expand
Is this relevant?
1999
1999
BACKGROUND AND OBJECTIVE New photosensitizers proposed for photodynamic therapy (PDT) treatment of tumors need to be evaluated in… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Photodynamic therapy (PDT) of pigmented melanoma has generally been unsuccessful because of insufficient light penetration in… Expand
Is this relevant?
1998
1998
Photodynamic therapy (PDT) of locally recurrent breast cancer has been limited to treatment of small lesions because of non… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Lutetium texaphyrin (PCI-0123) is a pure, water-soluble photodynamic therapy (PDT) agent that is activated by tissue-penetrating… Expand
Is this relevant?
1997
1997
Lutetium texaphyrin (PCI-0123) is presently in clinical trials for the treatment of neoplasms. An argon-pumped dye laser has… Expand
Is this relevant?
1997
1997
Cardiovascular disease is the chief cause of death in the western world. Lutetium texaphyrin (PCI-0123) is a pure, synthetic… Expand
Is this relevant?
1997
1997
Lutetium texaphyrin (PCI-0123) is currently in clinical trials as a PDT agent for the treatment of cancer patients. The drug is… Expand
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Lutetium texaphyrin, PCI-0123, is a pure, water-soluble photosensitizer with a large broad absorption band centered at 732 nm… Expand
Is this relevant?
1996
1996
Cancer and cardiovascular disease are the leading causes of death in the western world. Photodynamic therapy (PDT) has… Expand
Is this relevant?